Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.7% – What’s Next?

Posted by Geri Gentry on Aug 18th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) was up 3.7% during mid-day trading on Tuesday . The company traded as high as $1,228.47 and last traded at $1,227.1070. Approximately 2,446,088 shares changed hands during mid-day trading, a decline of 21% from the average daily volume of 3,097,944 shares. The stock had previously closed at $1,183.16.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Obesity-pill momentum: Lilly is reportedly narrowing Novo Nordisk’s early lead in the oral weight-loss market. Investor enthusiasm is being supported by expectations that Lilly’s obesity portfolio can extend its leadership beyond injectable GLP-1 treatments. Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills
Positive Sentiment: Retatrutide progress: Positive trial developments for retatrutide, Lilly’s next-generation obesity and metabolic-disease candidate, have prompted the company to lift related guidance. The drug could strengthen Lilly’s long-term growth outlook if late-stage results and regulatory progress remain favorable. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
Positive Sentiment: Pipeline expansion through licensing: Lilly entered a global collaboration with OmniAb for an ion-channel discovery program. The agreement, which includes potential milestone payments of up to $370 million, adds another avenue for future drug development and demonstrates continued investment in external innovation. OmniAb Enters Global Collaboration and License Agreement With Eli Lilly
Positive Sentiment: CNS pipeline transaction: Lilly paid AlzeCure a $10 million upfront amount in an initial transaction involving small-molecule candidates for Alzheimer’s disease and pain, broadening Lilly’s pipeline beyond its core diabetes and obesity franchises. AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction With Lilly
Neutral Sentiment: Lilly appointed Tayllit Aherdan to oversee operations in the United Arab Emirates, Qatar and Kuwait. The move supports regional execution but is unlikely to materially affect near-term earnings. Lilly Appoints Tayllit Aherdan
Negative Sentiment: Analysts continue to flag Lilly’s elevated valuation, competition from Novo Nordisk and other obesity-drug developers, and potential pricing and patent pressures. With shares having already delivered substantial long-term gains, strong future growth may be required to justify additional upside. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Guggenheim lifted their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. BMO Capital Markets restated an “outperform” rating and issued a $1,400.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Finally, Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

View Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Trading Up 3.7%

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock’s 50 day moving average is $1,171.52 and its 200-day moving average is $1,053.72. The company has a market cap of $1.16 trillion, a PE ratio of 41.18, a P/E/G ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 over the last ninety days. Company insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of the business. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Eli Lilly and Company during the 2nd quarter valued at $52,685,000. Twin Lakes Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $390,000. Strait & Sound Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $1,026,000. Rakuten Investment Management Inc. bought a new stake in Eli Lilly and Company during the second quarter valued at about $159,988,000. Finally, RB Capital Management LLC purchased a new position in Eli Lilly and Company in the second quarter valued at about $5,751,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.